The IPO market is expected to remain active in the week ahead with nine IPOs scheduled to raise $2.7 billion.
Canadian digital service provider TELUS International (TIXT) plans to raise $800 million at a $6.4 billion market cap. The...read more
Eight IPOs and nine SPACs entered the public markets this past week led by BigCommerce (BIGC), which soared 201% in the best first-day pop for an IPO over $100 million in 15 years.
E-commerce platform BigCommerce (BIGC)...read more
Checkmate Pharmaceuticals, a clinical stage immuno-oncology biotech developing therapies for solid tumors, raised $75 million by offering 5 million shares at $15, within the range of $14 to $16. Checkmate Pharmaceuticals plans to list on the Nasdaq under the...read more
Checkmate Pharmaceuticals, a clinical stage immuno-oncology biotech developing therapies for solid tumors, announced terms for its IPO on Monday.
The Cambridge, MA-based company plans to raise $75 million by offering 5 million shares at a price range of $14...read more
US IPO Week Ahead: Canadian IT and German chemicals lead a diverse 9 IPO week
The IPO market is expected to remain active in the week ahead with nine IPOs scheduled to raise $2.7 billion. Canadian digital service provider TELUS International (TIXT) plans to raise $800 million at a $6.4 billion market cap. The...read more
US IPO Weekly Recap: BigCommerce’s 201% first-day pop breaks records in an 8 IPO week
Eight IPOs and nine SPACs entered the public markets this past week led by BigCommerce (BIGC), which soared 201% in the best first-day pop for an IPO over $100 million in 15 years. E-commerce platform BigCommerce (BIGC)...read more
Checkmate Pharmaceuticals prices IPO at $15 midpoint
Checkmate Pharmaceuticals, a clinical stage immuno-oncology biotech developing therapies for solid tumors, raised $75 million by offering 5 million shares at $15, within the range of $14 to $16. Checkmate Pharmaceuticals plans to list on the Nasdaq under the...read more
Solid tumor biotech Checkmate Pharmaceuticals sets terms for $75 million IPO
Checkmate Pharmaceuticals, a clinical stage immuno-oncology biotech developing therapies for solid tumors, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $75 million by offering 5 million shares at a price range of $14...read more